Investment Thesis
Nutex Health demonstrates exceptional revenue growth (+82% YoY) with fortress-like fundamentals: excellent net margins (21.6%), strong free cash flow generation ($74.3M, 34.3% FCF margin), and minimal financial leverage (0.07x D/E). However, flat net income growth despite surging revenue suggests margin compression or prior-year timing issues requiring monitoring.
Strengths
- Exceptional revenue growth of 82% YoY demonstrates strong market demand and business traction
- Excellent profitability metrics: 21.6% net margin, 37.5% operating margin, and 42.4% gross margin
- Strong free cash flow generation of $74.3M (34.3% FCF margin) indicates genuine earnings quality and operational efficiency
- Fortress balance sheet with minimal debt (0.07x D/E), substantial cash position ($207.3M), and exceptional liquidity (3.14x current ratio)
- Asset-light business model evidenced by minimal capex requirements ($1.2M) and high cash conversion
Risks
- Net income growth flat at 0% YoY despite 82% revenue growth signals potential margin compression, operational leverage challenges, or prior-year comparison distortion
- Low return on assets (4.9%) relative to $957.3M asset base suggests significant assets may not be generating attractive returns
- Rapid 82% growth trajectory presents sustainability risks and potential execution challenges at scale
- Elevated insider trading activity (21 Form 4 filings in 90 days) warrants monitoring for potential insider selling pressure
Key Metrics to Watch
- Net income and EPS growth trajectory in subsequent quarters to confirm margin sustainability
- Gross margin and operating margin trends through growth phase to detect further compression
- Return on Assets improvement as revenue scales to validate capital efficiency
- Free cash flow consistency and conversion rates to confirm cash generation quality
- Insider transaction patterns - magnitude and direction of insider trading activity
Financial Metrics
Revenue
216.5M
Net Income
46.8M
EPS (Diluted)
$6.52
Free Cash Flow
74.3M
Total Assets
957.3M
Cash
207.3M
Profitability Ratios
Gross Margin
42.4%
Operating Margin
37.5%
Net Margin
21.6%
ROE
13.5%
ROA
4.9%
FCF Margin
34.3%
Balance Sheet & Liquidity
Current Ratio
3.14x
Quick Ratio
3.12x
Debt/Equity
0.07x
Debt/Assets
53.8%
Interest Coverage
18.28x
Long-term Debt
24.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:26:10.235074 |
Data as of: 2026-03-31 |
Powered by Claude AI